Effect of monoclonal antibodies to PCSK9 on high‐sensitivity C‐reactive protein levels: a meta‐analysis of 16 randomized controlled treatment arms

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging class of low‐density lipoprotein cholesterol (LDL‐C)‐lowering agents. In spite of their known effects on lipids, the impact of these drugs on systemic inflammation is less known. We aimed to investigate the effect...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Sahebkar, Amirhossein, Di Giosia, Paolo, Stamerra, Cosimo Andrea, Grassi, Davide, Pedone, Claudio, Ferretti, Gianna, Bacchetti, Tiziana, Ferri, Claudio, Giorgini, Paolo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Meta‐analysis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876179/
https://ncbi.nlm.nih.gov/pubmed/26861255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12905
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller